glp-1 orem Lemme Daily Capsules Editorial Review of Troomy GLP Lemme Reset™ GLP-1 Production Support

A 2024 pooled analysis of the SURMOUNT trials (Aronne et al., Lancet ) found that 4.3% of patients discontinued tirzepatide due to GI side effects

Meals marketed for GLP-1 users also are attracting non-users, including people who have come off the drugs but want to maintain weight loss

This guide walks through every piece of evidence, every contraindication, every monitoring recommendation, and every practical question that researchers with thyroid nodules face when evaluating tirzepatide therapy

Dwivedi Y, Rizavi HS, Conley RR, Roberts RC, Tamminga CA, Pandey GN

The OR for achieving a weight loss of at least 5% with tirzepatide 5 mg, 10 mg and 15 mg (vs GLP-1 RAs) was, respectively, 1.96 (95% CI 1.01, 3.80 [ I 2 61%]), 4.79 (95% CI 1.95, 11.73 [ I 2 74%]) and 4.57 (95% CI 3.38, 6.18 [ I 2 0%]) (ESM Table 2)